Company news

Lonza Group AG news in 2026

Lonza Group AG's news releases, calls and decks from 2026, newest first.

View company

Lonza Upgrades Organic Growth Model and Mid-term Financial Ambitions at Capital Markets Day; Q3 2026 In Line with Expectations

October 14, 2026

Lonza Expands Dual-Payload ADC Technology Offering Through Exclusive Access to Qurient’s CDK7 Inhibitors

October 12, 2026

Lonza Nominates Pearl Huang as Independent Board Member

September 30, 2026

Lonza Group: Further Strengthens US Manufacturing Presence with Addition of a Commercial Spray-Drying Facility in Bend, Oregon

September 10, 2026

Lonza Appoints Samanta Cimitan as Chief Commercial Officer

August 26, 2026

Leading the Future of Oral Delivery, Lonza Capsugel brings breakthrough Capsule Technologies to the Korean Market at CPHI Korea

August 5, 2026

Lonza Delivered Strong H1 2026 Performance Across All Business Platforms and Upgrades Full-Year 2026 Margin Outlook

July 22, 2026

Lonza Expands Strategic Collaboration with Leading US Biopharmaceutical Company

July 1, 2026

Lonza Expands HPAPI Capacity in Visp, Further Supporting its Position in Payload-Linker Manufacturing

June 30, 2026

Lonza Publishes Restated Half-Year 2025 Financials Reflecting Capsules & Health Ingredients as Discontinued Operations

June 23, 2026

Lonza Issues Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers

June 15, 2026

Lonza Appoints Hans Trees as Global Head of Communications

June 9, 2026

Lonza Announces Results of the 2026 Annual General Meeting – All Motions Proposed by Board of Directors Approved

May 8, 2026

Lonza Delivers Strong Performance in Q1 2026 in Line with Expectations and Confirms Full-Year Outlook 2026

May 8, 2026

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

April 21, 2026

Specialty Triglycerides Market Dominates Nutrition and Pharmaceutical Applications with Lonza, BASF, Stepan Company

April 1, 2026

Lonza Nominates Stephen Fry as Independent Board Member

March 31, 2026

Lonza and Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO™

March 9, 2026

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG

March 6, 2026

Changes to the Composition of the Lonza Board

February 13, 2026

Lonza Delivers Strong Profitable Growth in Full-Year 2025 and Successfully Completes Vacaville Site Integration

January 28, 2026

Lonza's Synaffix and Sidewinder Therapeutics Announce Multi-Target License Agreement to Advance Development of Next-Generation Bispecific ADCs

January 7, 2026

GBI Biomanufacturing Announces the Appointment of Jesse McCool, Ph.D. as President

January 6, 2026

Calls in 2026

Decks in 2026